For a patient with mixed connective tissue disease on azathioprine 50 mg daily, a history of uveitis, positive anti‑RNP antibodies and negative anti‑dsDNA and ENA, how should ovulation induction or in‑vitro fertilisation be managed and what are the associated risks?

Management of Ovulation Induction/IVF in Mixed Connective Tissue Disease

Continue azathioprine 50 mg daily throughout ovulation induction and IVF procedures, as azathioprine is pregnancy-compatible and should not be interrupted for fertility treatments in patients with stable disease. 1, 2

Medication Management During Fertility Treatment

Azathioprine Continuation

• Azathioprine is explicitly compatible with pregnancy and fertility procedures at doses up to 2 mg/kg daily (your patient's 50 mg dose is well within safe limits) 1
• The 2020 ACR guidelines strongly recommend continuation of necessary immunosuppressive therapies during ovarian stimulation for oocyte retrieval, specifically including azathioprine 2
• Discontinuing effective immunosuppression risks disease flare, which poses greater danger than continuing the medication 2
• Azathioprine can be safely continued throughout conception attempts, pregnancy, and even lactation (though with conditional recommendation for breastfeeding) 1, 2

Critical Distinction from Teratogenic Drugs

Unlike methotrexate, mycophenolate, or cyclophosphamide—which must be stopped before conception—azathioprine does not require discontinuation 1. This is a crucial point that distinguishes your patient's situation from other immunosuppressive regimens.

Disease-Specific Considerations for MCTD

Pre-Conception Assessment Required

Given the positive anti-RNP antibodies (diagnostic for MCTD), evaluate for:

• Antiphospholipid antibodies (aPL): Test for anticardiolipin, anti-β2 glycoprotein I, and lupus anticoagulant 2
• Disease activity status: Ensure MCTD is stable/in remission before proceeding
• Organ involvement: Particularly pulmonary (interstitial lung disease risk) and cardiac function
• History of uveitis activity: Current inflammatory status

If Antiphospholipid Antibodies Are Positive

• Start prophylactic LMWH (enoxaparin 40 mg daily) at the beginning of ovarian stimulation 2
• Withhold LMWH 24-36 hours before oocyte retrieval to minimize bleeding risk
• Resume immediately after retrieval
• Continue until estrogen levels normalize if no pregnancy occurs
• Add low-dose aspirin starting in first trimester if pregnancy achieved 2

If Antiphospholipid Antibodies Are Negative

• Low-dose aspirin starting in first trimester is conditionally recommended for MCTD/SLE-like disease 2
• No routine anticoagulation needed during ovulation induction

Risks and Monitoring

Maternal Risks During Fertility Treatment

Disease Flare Risk:

• High estrogen levels from ovarian stimulation can trigger lupus-like flares in MCTD
• Risk is significantly higher if immunosuppression is discontinued
• Consider ovarian stimulation protocols with aromatase inhibitors to achieve lower peak estrogen levels 2

Thrombotic Risk:

• Elevated if aPL-positive (even without prior thrombosis)
• Ovarian hyperstimulation syndrome increases thrombotic risk independent of aPL status
• LMWH prophylaxis addresses both concerns 2

Uveitis Reactivation:

• Monitor for ocular inflammation during hormonal stimulation
• Azathioprine provides ongoing protection (effective for steroid-resistant autoimmune uveitis) 3

Pregnancy Risks (If Conception Occurs)

With Azathioprine:

• No increased rate of congenital malformations at therapeutic doses 1
• Safe throughout all trimesters
• Monitor complete blood counts monthly (or more frequently if needed) 4
• Watch for maternal bone marrow suppression (dose-dependent, reversible)

MCTD-Specific Pregnancy Complications:

• Increased risk of preterm birth
• Pregnancy-induced hypertension/preeclampsia
• Disease flare (particularly in postpartum period)
• Fetal growth restriction if significant vascular involvement

Monitoring Protocol

Before Starting Fertility Treatment:

• Complete blood count with platelets
• Comprehensive metabolic panel (liver and kidney function)
• aPL panel (if not recently done)
• Disease activity assessment
• Uveitis evaluation by ophthalmology

During Ovulation Induction/IVF:

• CBC monitoring as clinically indicated
• Watch for signs of disease flare (arthritis, rash, serositis)
• Monitor for uveitis symptoms (pain, redness, photophobia, vision changes)

If Pregnancy Achieved:

• Continue azathioprine throughout pregnancy 1
• CBC monitoring monthly minimum 4
• Add low-dose aspirin 2
• Increase monitoring frequency for disease activity (at least once per trimester) 2
• Multidisciplinary care with maternal-fetal medicine

Common Pitfalls to Avoid

1. Do NOT stop azathioprine for fertility treatment—this is the most critical error to avoid. The guidelines explicitly support continuation 1, 2

2. Do NOT assume negative dsDNA means no lupus-like features—MCTD can have SLE overlap requiring similar pregnancy precautions 2

3. Do NOT forget aPL testing—even asymptomatic aPL carriers need anticoagulation during IVF 2

4. Do NOT use aspirin before oocyte retrieval if anticoagulation is needed—use LMWH instead due to aspirin's prolonged action and bleeding risk 2

5. Do NOT overlook TPMT testing—if your patient has had severe myelosuppression on azathioprine, consider TPMT/NUDT15 genotyping 4